Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 13/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL218331 | 0.73 | NOTUM (0.41) | NOTUM | |
| SCHEMBL29118314 | 0.72 | NOTUM (0.39) | NOTUM | |
| Ammonia Solution, Strong SCHEMBL7867000 | 0.72 | NOTUM (0.39) | NOTUM | |
| SCHEMBL28548337 | 0.71 | NOTUM (0.49) | NOTUMKEAP1CYP19A1 | |
| Ethane SCHEMBL16751833 | 0.71 | NOTUM (0.40) | NOTUM | |
| SCHEMBL9466419 | 0.70 | NPC1 (0.33) | — | |
| SCHEMBL13407536 | 0.69 | NOTUM (0.36) | NOTUMKEAP1 | |
| Piperazine SCHEMBL7865831 | 0.67 | NOTUM (0.35) | NOTUM | |
| SCHEMBL28456730 | 0.67 | NOTUM (0.50) | NOTUMKEAP1 | |
| Guanidine SCHEMBL7865811 | 0.66 | MAPT (0.40) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116574068-A | Universal energy-containing combustion speed catalyst, preparation method and application | 西安近代化学研究所 | 2023-08-11 | — | — | CN | disclosed |
| US-20050272789-A1 | Triazole-derived kinase inhibitors and uses thereof | HALE MICHAEL R | 2005-12-08 | — | — | US | disclosed |
| US-6962936-B2 | Triazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1390353-A1 | TRIAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20030158238-A1 | Triazole-derived kinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| WO-2002088097-A1 | TRIAZOLE-DERIVED KINASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158238-A1 | Triazole-derived kinase inhibitors and uses thereof | MAP3K1, MAP3K5, MAP3K19 | NOTUM 3764/4885KEAP1 1370/4885CYP19A1 2050/4885 |
| US-20050272789-A1 | Triazole-derived kinase inhibitors and uses thereof | MAP3K5, MAP3K1, MAP3K3 | NOTUM 3626/4885KEAP1 1378/4885CYP19A1 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.